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Summary
Ginkgo biloba is an herbal remedy can be found as an ingredient of many dietary supplements. Ginkgo contains 
 diﬀ erent biologically active compounds that can inhibit platelet aggregation. Prolonged platelet aggregation can have a 
positive eﬀ ect on the cardiovascular system in cancer patients undergoing chemotherapy, but in oncological surgery 
(in particular major abdominal, gynecological, and operations with reconstructions) it can increase risk of bleeding. 
 Consequently in these patients there is a need for perioperative assess of the impact of ginkgo on platelet aggregation. 
In this study we investigated the eﬀ ect of diﬀ erent supplements on platelet aggregation available on the free market 
which by declaration are containing ginkgo extract alone or in combination with other plants. The study was conducted on 
24 male rats Y59,  divided into 4 groups, depending on the herbal food supplements which was used for treatment. Platelet 
aggregation was determined on Multiplate analyzer, impedance aggregometry. Prolonged platelet aggregation was 
 measured in groups b ginkgo (P=0.025), c vulkan (P=0.004), d GOI (P=0.035) compared to control group when it was used 
ADP as agonist. Platelet aggregation where it was used collagen as agonist showed no statistically signifi cant diﬀ erence 
between groups.
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UČINAK PRIPRAVAKA GINKA NA AGREGACIJU TROMBOCITA U ŠTAKORA
Sažetak
Ekstrakt biljke Ginkgo biloba može se naći kao sastojak brojnih dodataka prehrani te imamo još registrirane biljne lije-
kove na bazi Ginka. Ginko sadrži različite biološki aktivne tvari koje mogu djelovati na inhibiciju agregacije trombocita što 
može pozitivno ali i negativno djelovati na kardiovaskularni sustav u onkoloških bolesnika na kemoterapiji, a kod onko-
loških operacija (naročito većih abdominalnih, ginekoloških, te operacija s rekonstrukcijom) povećan je rizik od krvarenja, 
te je kod takvih bolesnika potrebno perioperativno procijeniti utjecaj na agregaciju u slučaju korištenja pripravaka ginka. U 
ovom radu istražili smo učinak ginka i raznih suplemenata koji sadrže ginkgo na agregaciju trobocita. Ispitivanje je vršeno 
na 4 skupine po 6 muških štakora soja Y59, od kojih je jedna bila kontrola, a ostale tri su dobivale ginko i ginko s različitim 
biljnim dodacima. Agregacija trombocita mjerena je na Multiplate analizatoru, impedancijskom agregometru. Agregacija 
trombocita bila je produžena gdje smo u testiranju koristili ADP kao agonist u sve tri tretirane skupine u odnosu na kon-
trolu, skupini b ginkgo (P=0.025), c vulkan (P=0.004) i d GOI (P=0,035), dok agregacija s kolagenom kao agonistom nije bila 
statistički značajno produžena.




Herbal remedies, including ginkgo formula-
tions have many components that can aﬀ ect the 
metabolism of the cell (1). Commercially available 
herbal remedies of ginkgo are used to improve cir-
culation and cognitive function (2,3). Extract of 
ginkgo is one of the most popular plants used for 
medicinal purposes in the EU (4,5,6).
Extract of ginkgo (EGb 761) is recommended 
at dosages of 120 mg to a maximum dose of 240 
mg in humans. General opinion is that the ginkgo 
is well tolerated (7,8), although there has been re-
ported a series of unwanted side eﬀ ects: headache, 
dizziness, bleeding and gastrointestinal distur-
bances (3,9,8).
Oncology patients during treatment often 
use dietary supplements, and some of them can 
contain ginkgo which can aﬀ ect perioperativ 
bleeding during major oncologic surgeries. Gink-
go contains active compounds that can aﬀ ect the 
coagulation hemostasis (10). Several review arti-
cles (11,12) have described an increased risk of 
bleeding when taking ginkgo formulations.
Preparation of ginkgo in combination with 
ticlopidine (platelet ADP receptor antagonist, an-
tiaggregating eﬀ ect) compared to ticlopidine 
alone showed greater eﬃ  cacy in mice in protec-
tion from thromboembolic events (13). In now 
days it is increasingly probable that patient may 
have cancer and cardiovascular disease. Many dif-
ferent cytotoxic agents used to treat cancer, classic 
chemotherapy, monoclonal antibodies that target 
tyrosine kinase receptors, antiangiogenic drugs 
and chemoprevention agents such as COX-2 in-
hibitors can have infl uence on the cardiovascular 
system. It is desirable to fi nd potential protective 
agents that could be administered to patients with 
occult or overt risk for cardiovascular complica-
tions (14).
In this study we investigated the eﬀ ect of dif-
ferent supplements on platelet aggregation avail-
able on the free market which by declaration are 
containing ginkgo extract alone or in combination 
with other plants.
MATERIALS AND METHODS
The study was conducted on 24 male rats 
Y59, divided into 4 groups, depending on the 
herbal food supplements which was used for 
treatment. Animals were 4-6 months old, weigh-
ing 350-450 g from the cultivation of the Institute 
of Animal Physiology, Faculty of Science in Za-
greb. The preparations used in the study were 
Ginkocel (Preparation of ginkgo), Vulcan (mix-
ture ginkgo, hop, lemon balm and oregano) and 
GinkAlert (mixture ginkgo, blueberries and Gotu 
Cola). Group a was the control group, group b –
treated with Ginkocel, group c – with Vulcan, 
group d – with GinkAlertom.
Animals were treated once daily trough in-
tragastric tube with recommended daily dosage of 
ginkgo formulations for 14 days. Platelet aggrega-
tion was determined on Multiplate analyzer, im-
pedance aggregometry. Impedance aggregometry 
is based on the principle that the platelets are not 
thrombogenic when not activated, with activation 
they express receptors on the surface and allow 
the att achment to the damaged endothelium or ar-
tifi cial surface. Platelets adhere to the sensing elec-
trodes, enhanced electrical resistance between 
them is being measured. Each Multiplate measur-
ing well is contains two independent sensor units 
made of two copper electrodes. The instrument 
detects impedance change beatween two elec-
trodes. Impedance change is expressed as AU 
(eng. aggregation units). Coeﬃ  cient of correlation 
between two measurements is automatically cal-
culated. In the study we used two tests to assess 
platelet function, COL test (collagen) and ADP 
test (with adenosinediphosphate) (Roche diagnos-
tics reagents, according to the manufacturer’s in-
structions). Collagen activates collagen receptors 
and the ADP activates platelets via the ADP recep-
tors. 300 mL of 0.9% saline is placed in measuring 
well, then 300 mL of whole blood and then incu-
bated for 3 min. After incubation, we added 20 ml 
of a suitable reagent (collagen or ADP). Measur-
ing time takes 6 minutes and the result is obtained 
by calculating the area under the curve. Statistical 
analysis was performed using the program Statis-
tica. We used data obtained by the analysis of vari-
ants and gained insight into the correlation and 
diﬀ erences of the measured parameters between 
the groups. The diﬀ erences were confi rmed with 
the LSD post hoc test.
RESULTS
Prolonged platelet aggregation was measu-
red in groups b ginko (P=0.025), c vulkan (P=0.004), 
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d GOI (P=0.035) compared to control group when 
it was used ADP as agonist. (Figure 1)
Platelet aggregation where it was used colla-
gen as agonist showed no statistically signifi cant 
diﬀ erence between groups. (Figure 2)
DISSCUSION
Earlier studies cited possible mechanisms of 
ginkgo eﬀ ect on coagulation homeostasis through 
interaction with platelet factor 4 (PF4) and colla-
gen which leads to prolongation in platelet aggre-
gation (15,16). Studies showed that the active com-
pound of the gingko inhibit platelet aggregation 
by increasing the concentration of endothelial 
thrombolytic agents, such as nitric oxide (NO) and 
prostacyclins (17,18).
Ginkgolide B directly inhibits binding of 
platelet factor 4 (PF4) to receptors on the platelet 
membrane (15). Other researchers believe that 
ginkgo primarily aﬀ ects reaction between plate-
lets and collagen, but not on the platelet-activating 
factor (16). Cho and Nam (2007) in the study found 
that ginkgo inhibits platelet aggregation via gink-
golide B (GB). They found that the diﬀ erent con-
centrations of GB signifi cantly reduce platelet 
 aggregation stimulated by collagen, induces me-
talloproteinase-9 (MMP-9) which inhibits colla-
gen-stimulated platelet aggregation. They also 
found that GB directly acts on adenylate cyclase 
activity and cAMP-dependent phosphodiesterase 
(PDE) guanylate cyclase and cGMP dependant 
PDE. Increased levels of cAMP and cGMP indi-
rectly lead to activation of the enzymes protein 
kinase A and protein kinase G which phosphory-
late their target proteins leading to the negative 
regulation of platelet aggregation (19,20).
In this study, platelet aggregation was inhib-
ited in the groups b ginkgo, c Vulkan and d GOI 
where it was used ADP as an agonist (P=0.02, 
P=0.004, P=0.03). Possible mechanisms of action of 
Ginkgo on hemostasis is based on the inhibition of 
platelet activating factor (eng. Platelet activating 
factor, PAF) by ginkgolides B (21). Possible eﬀ ect 
of ginkgo fl avonoids on platelet aggregability by 
inhibition of various protein kinases could led 
lower concentration of PLC (phospholipase C) 
(22). Bojić et al (2011) in vitro showed that all ana-
lyzed fl avonoids, including quercetin and isorh-
amnetin (fl avonoides in ginkgo suplements used 
in this study) showed antiplatelet eﬀ ect. Much 
lower concentrations of fl avonoids are needed to 
inhibit aggregation when ADP was used in aggre-
gation assays (0.119 to 122 microns), in contrast to 
collagen-induced aggregation (15-244 uM) (23).
Since there is no data on the elimination half-
life of ginkgo, a recommendation to discontinue 
ginkgo supplementation prior to surgery lacks em-
pirical evidence. However, with the known impli-
cations of ginkgo on hemostasis, it would be pru-
dent to discontinue supplements a minimum of 5 
to 7 days prior to major oncologic surgery (24).
CONCLUSION
In our opinion, it is necessary to carry out 
further research on a larger number of samples 
Figure 1. The eﬀ ect of herbal suplements on platelet aggregation 
with ADP as agonist of aggregation. Lett ers a, b, c, d above the 
columns denote statistically signifi cant diﬀ erences (P≤0.05) be-
tween groups for platelet aggregation with ADP(a control grup, 
b Ginkocel treated group, c Vulkan treated group, d Ginkalert 
treated group). SD-standard deviation.
Figure 2. Eﬀ ect of herbal supplements on platelet aggregation 
with collagen as agonist of aggregation. There was no statistically 
signifi cant diﬀ erences between groups of experimental animals 
(a control grup, b Ginkocel treated group, c Vulkan treated group, 
d Ginkalert treated group). SD-standard deviation.
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with prolonged treatment and with the individual 
active compounds in order to clarify the molecu-
lar mechanisms of eﬀ ect on endothelium and he-
mostasis.
With these fi ndings it is necessary to assess 
the risk and benefi t ratio of ginkgo use in cancer 
patients during active treatment.
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